Heart failureIncremental Prognostic Power of Novel Biomarkers (Growth-Differentiation Factor-15, High-Sensitivity C-Reactive Protein, Galectin-3, and High-Sensitivity Troponin-T) in Patients With Advanced Chronic Heart Failure
Section snippets
Methods
The present study was conducted as a substudy from the Deventer-Alkmaar Heart Failure study (DEAL-HF), which has been described elsewhere.13, 14 In brief, 240 patients with typical signs and symptoms of chronic HF combined with findings of a reduced left ventricular ejection fraction (45%) or diastolic dysfunction, according to the 2001 guidelines for the diagnosis of HF of the European Society of Cardiology, were included.15 Main exclusion criteria were an expected survival of <1 year, kidney
Results
Characteristics of the study population are described in Table 1. Medical care was provided according to the guidelines of the European Society of Cardiology prevailing at the time of inclusion and execution of the study with optimal application of therapy (baseline medication, Table 1). At baseline, beta blockers were prescribed in 60% of the patients. This figure went up to 69% after 1 year of follow-up. Almost all patients used a blocker of the renin-angiotensin system (96%) and diuretic
Discussion
Our study examined the predictive power of GDF-15, hs -CRP, Gal-3, and hs-TnT incremental to NT-proBNP, with respect to long-term outcome in patients with advanced chronic HF. The main findings of the present study are that GDF-15, hs-CRP, and hs-TnT have independent predictive power for long-term mortality, incremental to established clinical and biochemical risk factors. GDF-15 showed to be the strongest prognosticator. Second, the presence of each individual marker significantly enhanced
Disclosures
BG Medicine, Inc., has rights related to Galectin-3 measurements. BG Medicine, Inc., provided an unrestricted research grant to the Department of Cardiology of the University Medical Center Groningen, which employs P.v.d.M., R.A.d.B., and D.J.v.V. D.J.v.V and R.A.d.B. have received consultancy and speakers fees from BG Medicine, Inc. The Deventer Cardiology Research department received an unrestricted research grant from BG Medicine, Inc. Roche Diagnostics performed laboratory assessments for
References (29)
- et al.
Brain natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction
J Am Coll Cardiol
(2013) - et al.
Natriuretic peptides
J Am Coll Cardiol
(2007) - et al.
Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure
J Am Coll Cardiol
(2007) - et al.
Combination of conventional biomarkers for risk stratification in chronic heart failure
J Cardiol
(2009) - et al.
Prediction of outcome by highly sensitive troponin T in outpatients with chronic systolic left ventricular heart failure
Am J Cardiol
(2012) Multimarker approach for heart failure management: perspectives and limitations
Pharmacol Res
(2011)- et al.
Usefulness of C-reactive protein and left ventricular diastolic performance for prognosis in patients with left ventricular systolic heart failure
Am J Cardiol
(2008) - et al.
Prognostic value of serial measurements of highly sensitive cardiac troponin I in stable outpatients with nonischemic chronic heart failure
Am Heart J
(2011) - et al.
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
Eur J Heart Fail
(2012) - et al.
High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure
Clin Chem
(2004)
Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial
Circulation
Multiple biomarkers for risk prediction in chronic heart failure
Circ Heart Fail
Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study
Clin Res Cardiol
Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction
Ann Med
Cited by (85)
Growth differentiation factor-15, a novel systemic biomarker of oxidative stress, inflammation, and cellular aging: Potential role in cardiovascular diseases
2021, American Heart Journal Plus: Cardiology Research and PracticeBiochemical and imaging markers in patients with thalassaemia
2021, Hellenic Journal of CardiologyGrowth Differentiation Factor 15 (GDF-15), a New Biomarker in Heart Failure Management
2023, Current Heart Failure Reports
A.A. Voors is funded through Grant 242209 from the European Commission FP7-Health-2009-BIOSTAT-CHF.
See page 836 for disclosure information.